Cure My Disease

Don't miss your cure!

 Log in / Sign up

Your smartwatch could soon warn you before you crash

NCT ID NCT07817550

Diagnosis Sponsor: Truway Health, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 14, 2026 · Last updated Sep 15, 2026 · Updated 1 time

Summary

Researchers are testing whether combining data from wearables and remote monitors can predict a sudden health decline within 72 hours. The study will follow 10,000 adults aged 18 to 90 and collect signals such as heart rhythm, oxygen levels, temperature, gait, sleep, voice, and cough. Instead of looking at one vital sign alone, the team will track how these signals change together over time. The goal is to see if a multimodal digital biomarker model can accurately flag impending deterioration.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
multimodal digital biomarker monitoring using wearables and remote devices
What this could lead to
If it works, doctors could get an early warning system that flags a patient's decline days before it becomes obvious, using everyday wearables.
What could go wrong
This is an observational study, so it cannot prove that acting on the alerts saves lives. Wearable signals can be noisy, and a model that performs well in one group may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 10,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2026

Expected to finish

Mar 2039

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

FUSION-72 will enroll an adult longitudinal cohort for prospective evaluation of multimodal digital biomarkers associated with acute clinical deterioration. Participants will undergo protocol-specified collection of wearable and remote digital measurements, including ECG, PPG, oxygen saturation, temperature, gait, sleep, voice, cough, and participant-reported symptoms. The study is designed to evaluate temporal and cross-signal relationships and their ability to predict protocol-defined clinical deterioration within 72 hours.

Ages

18 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18 through 90 years at enrollment. * Able to provide informed consent, or have a legally authorized representative provide consent when permitted by the applicable protocol and regulations. * Able and willing to participate in prospective longitudinal digital biomarker monitoring. * Able to use, or permit application of, study-authorized wearable or remote-monitoring technologies. * Able and willing to provide protocol-specified physiologic, behavioral, acoustic, and symptom data. * Expected to have sufficient follow-up to permit evaluation of the 72-hour prediction endpoint. * Willing to comply with study procedures and data-collection requirements. Exclusion Criteria: * Inability to provide informed consent or otherwise participate through an approved consent process. * Clinical or technical circumstances that prevent reliable collection of the required multimodal digital biomarker data. * Inability or unwillingness to comply with study monitoring procedures. * Enrollment in another study that, in the investigator's judgment, would materially interfere with FUSION-72 data collection or endpoint assessment. * Any circumstance that, in the investigator's judgment, would make participation inappropriate or compromise the integrity of the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute disease Critical Illness Disease Progression

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute disease Aging Biomarkers Critical illness Digital health Disease progression Remote patient monitoring Wearable electronic devices

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Truway Health, Inc.

    New York, New York, 10016, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.